Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Research Articles: Therapeutics, Targets, and Development

  • Research Articles: Therapeutics, Targets, and Development
    Laser postionization secondary neutral mass spectrometry in tissue: a powerful tool for elemental and molecular imaging in the development of targeted drugs
    Andrea Wittig, Heinrich F. Arlinghaus, Christian Kriegeskotte, Raymond L. Moss, Klaas Appelman, Kurt W. Schmid and Wolfgang A.G. Sauerwein
    Mol Cancer Ther July 1 2008 7 (7) 1763-1771; DOI:10.1158/1535-7163.MCT-08-0191

  • Research Articles: Therapeutics, Targets, and Development
    Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair
    Mahmoud Toulany, Rainer Kehlbach, Urszula Florczak, Ali Sak, Shaomeng Wang, Jianyong Chen, Markus Lobrich and H. Peter Rodemann
    Mol Cancer Ther July 1 2008 7 (7) 1772-1781; DOI:10.1158/1535-7163.MCT-07-2200

  • Research Articles: Therapeutics, Targets, and Development
    eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling
    Alpana Soni, Argun Akcakanat, Gopal Singh, David Luyimbazi, Yuhuan Zheng, Doyil Kim, Ana Gonzalez-Angulo and Funda Meric-Bernstam
    Mol Cancer Ther July 1 2008 7 (7) 1782-1788; DOI:10.1158/1535-7163.MCT-07-2357

  • Research Articles: Therapeutics, Targets, and Development
    Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways
    Tingfang Yi, Sung-Gook Cho, Zhengfang Yi, Xiufeng Pang, Melissa Rodriguez, Ying Wang, Gautam Sethi, Bharat B. Aggarwal and Mingyao Liu
    Mol Cancer Ther July 1 2008 7 (7) 1789-1796; DOI:10.1158/1535-7163.MCT-08-0124

  • Research Articles: Therapeutics, Targets, and Development
    Antiproliferative effect of sulindac in colonic neoplasia prevention: role of COOH-terminal Src kinase
    Dhananjay P. Kunte, Ramesh K. Wali, Jennifer L. Koetsier and Hemant K. Roy
    Mol Cancer Ther July 1 2008 7 (7) 1797-1806; DOI:10.1158/1535-7163.MCT-08-0022

  • Research Articles: Therapeutics, Targets, and Development
    Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma
    Hui Guan, Zhichao Zhou, Gary E. Gallick, Shu-Fang Jia, Jaime Morales, Anil K. Sood, Seth J. Corey and Eugenie S. Kleinerman
    Mol Cancer Ther July 1 2008 7 (7) 1807-1816; DOI:10.1158/1535-7163.MCT-08-0058

  • Research Articles: Therapeutics, Targets, and Development
    Silibinin inhibits cytokine-induced signaling cascades and down-regulates inducible nitric oxide synthase in human lung carcinoma A549 cells
    Manesh Chittezhath, Gagan Deep, Rana P. Singh, Chapla Agarwal and Rajesh Agarwal
    Mol Cancer Ther July 1 2008 7 (7) 1817-1826; DOI:10.1158/1535-7163.MCT-08-0256

  • Research Articles: Therapeutics, Targets, and Development
    Active roles for inhibitory κB kinases α and β in nuclear factor-κB–mediated chemoresistance to doxorubicin
    Brian K. Bednarski, Xiaoyu Ding, Kavita Coombe, Albert S. Baldwin and Hong J. Kim
    Mol Cancer Ther July 1 2008 7 (7) 1827-1835; DOI:10.1158/1535-7163.MCT-08-0321

  • Research Articles: Therapeutics, Targets, and Development
    Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models
    Dimitri Pchejetski, Nicolas Doumerc, Muriel Golzio, Maria Naymark, Justin Teissié, Takafumi Kohama, Jonathan Waxman, Bernard Malavaud and Olivier Cuvillier
    Mol Cancer Ther July 1 2008 7 (7) 1836-1845; DOI:10.1158/1535-7163.MCT-07-2322

  • Research Articles: Therapeutics, Targets, and Development
    Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells
    Dongwei Zhang, Ashutosh Pal, William G. Bornmann, Fumiyuki Yamasaki, Francisco J. Esteva, Gabriel N. Hortobagyi, Chandra Bartholomeusz and Naoto T. Ueno
    Mol Cancer Ther July 1 2008 7 (7) 1846-1850; DOI:10.1158/1535-7163.MCT-08-0168

  • Research Articles: Therapeutics, Targets, and Development
    Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
    Sauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen, Pascal Furet, Christian Schnell, Christine Fritsch, Saskia Brachmann, Patrick Chène, Alain De Pover, Kevin Schoemaker, Doriano Fabbro, Daniela Gabriel, Marjo Simonen, Leon Murphy, Peter Finan, William Sellers and Carlos García-Echeverría
    Mol Cancer Ther July 1 2008 7 (7) 1851-1863; DOI:10.1158/1535-7163.MCT-08-0017

  • Research Articles: Therapeutics, Targets, and Development
    Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation
    Atsushi Tomioka, Motoyoshi Tanaka, Marco A. De Velasco, Satoshi Anai, Satoshi Takada, Toshihiro Kushibiki, Yasuhiko Tabata, Charles J. Rosser, Hirotsugu Uemura and Yoshihiko Hirao
    Mol Cancer Ther July 1 2008 7 (7) 1864-1870; DOI:10.1158/1535-7163.MCT-07-2198

  • Research Articles: Therapeutics, Targets, and Development
    A novel combination: ranpirnase and rosiglitazone induce a synergistic apoptotic effect by down-regulating Fra-1 and Survivin in cancer cells
    Maria E. Ramos-Nino and Benjamin Littenberg
    Mol Cancer Ther July 1 2008 7 (7) 1871-1879; DOI:10.1158/1535-7163.MCT-08-0308

  • Research Articles: Therapeutics, Targets, and Development
    Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
    Andrea J. Gonzales, Kenneth E. Hook, Irene W. Althaus, Paul A. Ellis, Erin Trachet, Amy M. Delaney, Patricia J. Harvey, Teresa A. Ellis, Danielle M. Amato, James M. Nelson, David W. Fry, Tong Zhu, Cho-Ming Loi, Stephen A. Fakhoury, Kevin M. Schlosser, Karen E. Sexton, R. Thomas Winters, Jessica E. Reed, Alex J. Bridges, Daniel J. Lettiere, Deborah A. Baker, Jianxin Yang, Helen T. Lee, Haile Tecle and Patrick W. Vincent
    Mol Cancer Ther July 1 2008 7 (7) 1880-1889; DOI:10.1158/1535-7163.MCT-07-2232

  • Research Articles: Therapeutics, Targets, and Development
    Single-chain antibody/activated BID chimeric protein effectively suppresses HER2-positive tumor growth
    Xiu-Chun Qiu, Yan-Ming Xu, Fang Wang, Qing-Yu Fan, Li-Feng Wang, Bao-An Ma, Lin-Tao Jia, Jing Zhao, Yan-Ling Meng, Li-Bo Yao, Si-Yi Chen and An-Gang Yang
    Mol Cancer Ther July 1 2008 7 (7) 1890-1899; DOI:10.1158/1535-7163.MCT-07-2235

  • Research Articles: Therapeutics, Targets, and Development
    Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer
    Danica L. Rowe, Tuba Ozbay, Laura M. Bender and Rita Nahta
    Mol Cancer Ther July 1 2008 7 (7) 1900-1908; DOI:10.1158/1535-7163.MCT-08-0012

  • Research Articles: Therapeutics, Targets, and Development
    c-Jun knockdown sensitizes osteosarcoma to doxorubicin
    Crispin R. Dass, Levon M. Khachigian and Peter F.M. Choong
    Mol Cancer Ther July 1 2008 7 (7) 1909-1912; DOI:10.1158/1535-7163.MCT-08-0086

  • Research Articles: Therapeutics, Targets, and Development
    Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis
    Laura P. Stabile, Mary E. Rothstein, Phouthone Keohavong, Jide Jin, Jinling Yin, Stephanie R. Land, Sanja Dacic, The Minh Luong, K. Jin Kim, Austin M. Dulak and Jill M. Siegfried
    Mol Cancer Ther July 1 2008 7 (7) 1913-1922; DOI:10.1158/1535-7163.MCT-07-2169

  • Research Articles: Therapeutics, Targets, and Development
    Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
    Akihiko Miyanaga, Akihiko Gemma, Rintaro Noro, Kiyoko Kataoka, Kuniko Matsuda, Michiya Nara, Tetsuya Okano, Masahiro Seike, Akinobu Yoshimura, Akiko Kawakami, Haruka Uesaka, Hiroki Nakae and Shoji Kudoh
    Mol Cancer Ther July 1 2008 7 (7) 1923-1930; DOI:10.1158/1535-7163.MCT-07-2140

  • Research Articles: Therapeutics, Targets, and Development
    Array-based analysis of the effects of trichostatin A and CG-1521 on cell cycle and cell death in LNCaP prostate cancer cells
    Somdutta Roy, Randy Jeffrey and Martin Tenniswood
    Mol Cancer Ther July 1 2008 7 (7) 1931-1939; DOI:10.1158/1535-7163.MCT-07-2353

  • Research Articles: Therapeutics, Targets, and Development
    Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis
    Marianne Kraus, Elke Malenke, Jeannette Gogel, Holger Müller, Thomas Rückrich, Herman Overkleeft, Huib Ovaa, Ewa Koscielniak, Jörg Thomas Hartmann and Christoph Driessen
    Mol Cancer Ther July 1 2008 7 (7) 1940-1948; DOI:10.1158/1535-7163.MCT-07-2375

  • Research Articles: Therapeutics, Targets, and Development
    Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-κB and activator protein-1 related mechanisms
    Zhong Chen, Justin L. Ricker, Pramit S. Malhotra, Liesl Nottingham, Lorena Bagain, Tin Lap Lee, Ning T. Yeh and Carter Van Waes
    Mol Cancer Ther July 1 2008 7 (7) 1949-1960; DOI:10.1158/1535-7163.MCT-07-2046

  • Research Articles: Therapeutics, Targets, and Development
    Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity
    Richard Sullivan, Geneviève C. Paré, Lisa J. Frederiksen, Gregg L. Semenza and Charles H. Graham
    Mol Cancer Ther July 1 2008 7 (7) 1961-1973; DOI:10.1158/1535-7163.MCT-08-0198

  • Research Articles: Therapeutics, Targets, and Development
    Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1α and -2α
    Maura Puppo, Florinda Battaglia, Catherine Ottaviano, Silvana Delfino, Domenico Ribatti, Luigi Varesio and Maria Carla Bosco
    Mol Cancer Ther July 1 2008 7 (7) 1974-1984; DOI:10.1158/1535-7163.MCT-07-2059

  • Research Articles: Therapeutics, Targets, and Development
    HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair
    Thuy T. Koll, Steven S. Feis, Mollie H. Wright, Modupe M. Teniola, Mekel M. Richardson, Ana I. Robles, John Bradsher, Jacek Capala and Lyuba Varticovski
    Mol Cancer Ther July 1 2008 7 (7) 1985-1992; DOI:10.1158/1535-7163.MCT-07-2104

  • Research Articles: Therapeutics, Targets, and Development
    S1P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells
    Dongmei Wang, Zhenwen Zhao, Andrea Caperell-Grant, Gong Yang, Samuel C. Mok, Jinsong Liu, Robert M. Bigsby and Yan Xu
    Mol Cancer Ther July 1 2008 7 (7) 1993-2002; DOI:10.1158/1535-7163.MCT-08-0088

  • Research Articles: Therapeutics, Targets, and Development
    Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase
    Tatiana Okouneva, Olga Azarenko, Leslie Wilson, Bruce A. Littlefield and Mary Ann Jordan
    Mol Cancer Ther July 1 2008 7 (7) 2003-2011; DOI:10.1158/1535-7163.MCT-08-0095

  • Research Articles: Therapeutics, Targets, and Development
    Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration
    Gang-Ming Zou and Anirban Maitra
    Mol Cancer Ther July 1 2008 7 (7) 2012-2021; DOI:10.1158/1535-7163.MCT-08-0113

  • Research Articles: Therapeutics, Targets, and Development
    Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression
    Jimmy M-M. Kwok, Stephen S. Myatt, Charles M. Marson, R. Charles Coombes, Demetra Constantinidou and Eric W-F. Lam
    Mol Cancer Ther July 1 2008 7 (7) 2022-2032; DOI:10.1158/1535-7163.MCT-08-0188

  • Research Articles: Therapeutics, Targets, and Development
    Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity
    Lourdes Roque-Navarro, Krittalak Chakrabandhu, Joel de León, Sandra Rodríguez, Carlos Toledo, Adriana Carr, Cristina Mateo de Acosta, Anne-Odile Hueber and Rolando Pérez
    Mol Cancer Ther July 1 2008 7 (7) 2033-2041; DOI:10.1158/1535-7163.MCT-08-0222

  • Research Articles: Therapeutics, Targets, and Development
    Chemoprevention by perillyl alcohol coupled with viral gene therapy reduces pancreatic cancer pathogenesis
    Irina V. Lebedeva, Zhao-zhong Su, Nichollaq Vozhilla, Lejuan Chatman, Devanand Sarkar, Paul Dent, Mohammad Athar and Paul B. Fisher
    Mol Cancer Ther July 1 2008 7 (7) 2042-2050; DOI:10.1158/1535-7163.MCT-08-0245

  • Research Articles: Therapeutics, Targets, and Development
    Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968
    Claudio Pisano, Michelandrea De Cesare, Giovanni Luca Beretta, Valentina Zuco, Graziella Pratesi, Sergio Penco, Loredana Vesci, Rosanna Foderà, Fabiana Fosca Ferrara, Mario Berardino Guglielmi, Paolo Carminati, Sabrina Dallavalle, Gabriella Morini, Lucio Merlini, Augusto Orlandi and Franco Zunino
    Mol Cancer Ther July 1 2008 7 (7) 2051-2059; DOI:10.1158/1535-7163.MCT-08-0266

  • Research Articles: Therapeutics, Targets, and Development
    Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone
    Pawan Kumar, Qinghong Gao, Yu Ning, Zhuo Wang, Paul H. Krebsbach and Peter J. Polverini
    Mol Cancer Ther July 1 2008 7 (7) 2060-2069; DOI:10.1158/1535-7163.MCT-08-0287

  • Research Articles: Therapeutics, Targets, and Development
    Proteomic characterization of cytoskeletal and mitochondrial class III β-tubulin
    Lucia Cicchillitti, Roberta Penci, Michela Di Michele, Flavia Filippetti, Domenico Rotilio, Maria Benedetta Donati, Giovanni Scambia and Cristiano Ferlini
    Mol Cancer Ther July 1 2008 7 (7) 2070-2079; DOI:10.1158/1535-7163.MCT-07-2370

  • Research Articles: Therapeutics, Targets, and Development
    Antiangiogenic vinflunine affects EB1 localization and microtubule targeting to adhesion sites
    Stéphane Honoré, Alessandra Pagano, Géraldine Gauthier, Véronique Bourgarel-Rey, Pascal Verdier-Pinard, Karine Civiletti, Anna Kruczynski and Diane Braguer
    Mol Cancer Ther July 1 2008 7 (7) 2080-2089; DOI:10.1158/1535-7163.MCT-08-0156

  • Research Articles: Therapeutics, Targets, and Development
    Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts
    Francescopaolo Di Cello, Joelle Hillion, Jeanne Kowalski, Brigitte M. Ronnett, Abimbola Aderinto, David L. Huso and Linda M.S. Resar
    Mol Cancer Ther July 1 2008 7 (7) 2090-2095; DOI:10.1158/1535-7163.MCT-07-2282

  • Research Articles: Therapeutics, Targets, and Development
    Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-α-dependent and estrogen receptor-α-independent mechanisms
    Xinghua Long, Meiyun Fan, Robert M. Bigsby and Kenneth P. Nephew
    Mol Cancer Ther July 1 2008 7 (7) 2096-2108; DOI:10.1158/1535-7163.MCT-07-2350

  • Research Articles: Therapeutics, Targets, and Development
    5,5′-Dibromo-bis(3′-indolyl)methane induces Krüppel-like factor 4 and p21 in colon cancer cells
    Sung Dae Cho, Sudhakar Chintharlapalli, Maen Abdelrahim, Sabitha Papineni, Shengxi Liu, Jingjing Guo, Ping Lei, Ala Abudayyeh and Stephen Safe
    Mol Cancer Ther July 1 2008 7 (7) 2109-2120; DOI:10.1158/1535-7163.MCT-07-2311

  • Research Articles: Therapeutics, Targets, and Development
    Differential antiproliferative mechanisms of novel derivative of benzimidazo[1,2-α]quinoline in colon cancer cells depending on their p53 status
    Mirela Sedic, Miroslav Poznic, Peter Gehrig, Mike Scott, Ralph Schlapbach, Marijana Hranjec, Grace Karminski-Zamola, Kresimir Pavelic and Sandra Kraljevic Pavelic
    Mol Cancer Ther July 1 2008 7 (7) 2121-2132; DOI:10.1158/1535-7163.MCT-07-2261

  • Research Articles: Therapeutics, Targets, and Development
    Antimigratory effect of TK1-2 is mediated in part by interfering with integrin α2β1
    Hyun-Kyung Kim, Dae-Shik Oh, Sang-Bae Lee, Jung-Min Ha and Young Ae Joe
    Mol Cancer Ther July 1 2008 7 (7) 2133-2141; DOI:10.1158/1535-7163.MCT-07-2405

  • Research Articles: Therapeutics, Targets, and Development
    Prostate-specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability
    Sigrid A. Rajasekaran, Jason J. Christiansen, Ingrid Schmid, Eri Oshima, Kathleen Sakamoto, Jasminder Weinstein, Nagesh P. Rao and Ayyappan K. Rajasekaran
    Mol Cancer Ther July 1 2008 7 (7) 2142-2151; DOI:10.1158/1535-7163.MCT-08-0005

  • Research Articles: Therapeutics, Targets, and Development
    Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin
    Olga Kovalchuk, Jody Filkowski, James Meservy, Yaroslav Ilnytskyy, Volodymyr P. Tryndyak, Vasyl' F. Chekhun and Igor P. Pogribny
    Mol Cancer Ther July 1 2008 7 (7) 2152-2159; DOI:10.1158/1535-7163.MCT-08-0021

  • Research Articles: Therapeutics, Targets, and Development
    RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis
    Robert E. Miller, Martine Roudier, Jon Jones, Allison Armstrong, Jude Canon and William C. Dougall
    Mol Cancer Ther July 1 2008 7 (7) 2160-2169; DOI:10.1158/1535-7163.MCT-08-0046

  • Research Articles: Therapeutics, Targets, and Development
    Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation
    Jing Zhou, Guo-Dong Lu, Chye-Sun Ong, Choon-Nam Ong and Han-Ming Shen
    Mol Cancer Ther July 1 2008 7 (7) 2170-2180; DOI:10.1158/1535-7163.MCT-08-0071

  • Research Articles: Therapeutics, Targets, and Development
    Cloning and apoptosis-inducing activities of canine and feline TRAIL
    Sing Rong, Jenny H. Cai and Jennifer Andrews
    Mol Cancer Ther July 1 2008 7 (7) 2181-2191; DOI:10.1158/1535-7163.MCT-07-2139

  • Research Articles: Therapeutics, Targets, and Development
    Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa
    Yang Meng, Wenhua Tang, Yao Dai, Xiaoqing Wu, Meilan Liu, Qing Ji, Min Ji, Kenneth Pienta, Theodore Lawrence and Liang Xu
    Mol Cancer Ther July 1 2008 7 (7) 2192-2202; DOI:10.1158/1535-7163.MCT-08-0333

  • Research Articles: Therapeutics, Targets, and Development
    Down-regulation of X-linked inhibitor of apoptosis synergistically enhanced peroxisome proliferator-activated receptor γ ligand-induced growth inhibition in colon cancer
    Liang Qiao, Yun Dai, Qing Gu, Kwok Wah Chan, Bing Zou, Juan Ma, Jide Wang, Hui Y. Lan and Benjamin C.Y. Wong
    Mol Cancer Ther July 1 2008 7 (7) 2203-2211; DOI:10.1158/1535-7163.MCT-08-0326

  • Research Articles: Therapeutics, Targets, and Development
    The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor–induced apoptosis
    Shruti M. Raja, Shuzhen Chen, Ping Yue, Timothy M. Acker, Benjamin Lefkove, Jack L. Arbiser, Fadlo R. Khuri and Shi-Yong Sun
    Mol Cancer Ther July 1 2008 7 (7) 2212-2223; DOI:10.1158/1535-7163.MCT-07-2409

  • Research Articles: Therapeutics, Targets, and Development
    Key role for Bak activation and Bak-Bax interaction in the apoptotic response to vinblastine
    Meenakshi Upreti, Rong Chu, Elena Galitovskaya, Sherri K. Smart and Timothy C. Chambers
    Mol Cancer Ther July 1 2008 7 (7) 2224-2232; DOI:10.1158/1535-7163.MCT-07-2299

  • Research Articles: Therapeutics, Targets, and Development
    Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids
    Margaret E. Ackerman, David Pawlowski and K. Dane Wittrup
    Mol Cancer Ther July 1 2008 7 (7) 2233-2240; DOI:10.1158/1535-7163.MCT-08-0067

  • Research Articles: Therapeutics, Targets, and Development
    A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity
    Nicole Huebener, Stefan Fest, Anne Strandsby, Elke Michalsky, Robert Preissner, Yan Zeng, Gerhard Gaedicke and Holger N. Lode
    Mol Cancer Ther July 1 2008 7 (7) 2241-2251; DOI:10.1158/1535-7163.MCT-08-0109

  • Research Articles: Therapeutics, Targets, and Development
    Synergistic tumoricidal effect of combined hMUC1 vaccination and hNIS radioiodine gene therapy
    Yong Hyun Jeon, Yun Choi, Sun Och Yoon, Chul Woo Kim and June-Key Chung
    Mol Cancer Ther July 1 2008 7 (7) 2252-2260; DOI:10.1158/1535-7163.MCT-08-0277

Correction

  • Correction
    Article on CIC-3 and cancer drug resistance
    Mol Cancer Ther July 1 2008 7 (7) 2261-2261; DOI:10.1158/1535-7163.MCT-07-7-COR

Back to top
PreviousNext
Molecular Cancer Therapeutics: 7 (7)
July 2008
Volume 7, Issue 7
  • Table of Contents
  • About the Cover

Sign up for alerts

Issue Highlights

  • Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Jump to

  • Research Articles: Therapeutics, Targets, and Development
  • Correction
Advertisement
  • Most Cited
  • Most Read
Loading
  • CD137 Agonist mAb with Reduced Liver Toxicity
  • Truncated BRCA2 Contributes to PARPi Resistance
  • ERPAS to Predict Response to Endocrine Therapy
  • CDK8/19 Inhibitors Enhance NK-Cell–Mediated Cancer Therapy
  • Sialoglycan mAb for Cancer Immunotherapy
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement